Portal de Periódicos da CAPES

Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples

2020; International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts; Volume: 40; Issue: 11 Linguagem: Inglês

10.21873/anticanres.14643

1791-7530

Martin Filipits, Matthias Preusser, Johannes A. Hainfellner, Sabine Spiegl‐Kreinecker, Anna S. Berghoff, Edwin W. Lai, Kriszten Kocmond, Andrew Kohlway, Jodi Weidler, Michael Bates, Christopher L. Corless,

Histone Deacetylase Inhibitors Research

Background/Aim: To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and Methods: The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results: The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion: Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.